



# UNIVERSITĀTS**medizin.**

**MAINZ** 



# Quantitative Proteomanalyse: Grundlagen und Anwendung in der biomedizinischen Forschung

Univ.-Prof. Dr. Stefan Tenzer Institut für Immunologie

Pharmaforum 2017

#### **Our Group**



**Core Facility for Mass Spectrometry:** 

Head: Univ.-Prof. Dr. Stefan Tenzer

Postdoc: Dr. Ute Distler

Bioinformatics: Dr. Jörg Kuharev

**Technical Assistant: Ruben Spohrer** 

Funding: DFG, BMBF, FZI, FTN





#### Waters Synapt G2-Si

- ion mobility separation
- identification and quantification of up to 5000 proteins

## **Label-free quantitative Proteomics**







#### **Stringent identification criteria:**


UniProtKB/Swissprot reference proteome Reversed decoy database Minimum 2 peptides/ protein 1% FDR at peptide and protein level



Mass Spectrometric Analysis
Synapt G2-Si HDMS
(25.000 FWHM Resolution)

# Ion mobility enhanced proteomics






# **Method Development – MS analysis**




# High proteome coverage workflow


#### **Optimized Sample Preparation**



# Overlap between technical replicates



# High precision label-free quantification



- → over 4000 proteins using 180 min-gradients
- → High reproducibility and quantitative precision

#### **Selected Applications:**




- Defining the interactions between Nanoparticles and Proteins: The "Protein Corona"
- Identification of Protein Interaction Partners

- Tumor Biomarker Discovery
- Profiling Cellular Reactions to Bioactive Compounds


## **Applications: The Protein Corona**








## **Applications: Protein interactions**











# **Applications: Tumor Biomarkers**




	<b>Tumor Type</b>	TNM
	Adeno-Ca	T2aN1
	Adeno-Ca	T2aN1
	Adeno-Ca	T1bN0
	Adeno-Ca	T2aN0
7-17	Adeno-Ca	T3N0
-122	Adeno-Ca	T2aN0
$d > M_{A} \wedge$	Adeno-Ca	T2aN1
	Adeno-Ca	T3N1
	Adeno-Ca	T3N2
	SCC	T1aN0
	SCC	T1bN0
	SCC	T2bN0
	SCC	T2aN0
	SCC	T2bN1
	SCC	T3N0
	SCC	T2aN1
	SCC	T3N0
	SCC	T4N2

> clear separation of lung cancer and control samples

## **Applications: Effector Proteomics**



#### How does a cell react to a pharmaceutical compound?



# **Acknowledgements**



#### Nanoparticles /Protein Corona:

Sandra Ritz Prof. Volker Mailänder Dominik Docter Prof. Roland Stauber

#### **Lung Carcinoma Study**

Petra Leidinger Prof. Andreas Keller

#### **RALY-Interactome**

Albertomaria Moro Prof. Paolo Macchi

#### **Funding**







